bota20130704_8k.htm

 

 

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 


FORM 8-K

 

 



CURRENT REPORT


Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 1, 2013

 



Biota Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 



 

 

 

 

 

 

Delaware

 

001-35285

 

59-1212264

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

2500 Northwinds Parkway, Suite 100

Alpharetta, GA

 

30009

(Address of principal executive offices)

 

(Zip Code)


Registrant’s telephone number, including area code: (678) 221-3351          


Not applicable

(Former name or former address, if changed since last report)

 


 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory

Arrangements of Certain Officers.

 

(b)      Biota Pharmaceuticals, Inc. (the “Company”) terminated Ron Kocak, the Company’s former Corporate Controller and Chief Accounting Officer, effective July 1, 2013. The duties and responsibilities of the principal accounting officer will be assumed by Peter Azzarello, the Company’s Vice President of Finance.

 

 
 

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Biota Pharmaceuticals, Inc.

 
       
        

Date: July 5, 2013

/s/ Russell H Plumb  
 

Nam:

Russell H Plumb

 
 

Title:

President and Chief Executive Officer

(Duly Authorized Officer)